Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2016-06-07 Share Issue/Capital Cha…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document title is "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation (French financial regulator). The content provides a table detailing the total number of shares and voting rights as of May 31, 2016. This type of regular disclosure regarding the total share capital and voting rights structure is a specific regulatory requirement, often related to capital changes or major shareholdings, but the structure strongly aligns with disclosures about the capital base itself. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the most appropriate fit as it deals directly with the composition of the share capital and voting rights, which are fundamental components of capital structure reporting. It is not a general earnings release (ER), an interim report (IR), or a director's dealing (DIRS).
2016-06-07 French
Communicated under the obligation to provide permanent information / Other communications
Share Issue/Capital Change Classification · 98% confidence The document is an announcement dated June 6, 2016, detailing the launch of an employee shareholding plan by Ipsen. It discusses the purpose, context (shareholders' delegation), terms (subscription price, lock-up period), and schedule for the issuance of new shares reserved for employees. This activity directly relates to changes in the company's capital structure involving the issuance of new shares to employees, which aligns precisely with the definition of 'Share Issue/Capital Change' (SHA). It is not a general financing update (CAP), a director's dealing (DIRS), or a transaction in own shares (POS, which usually implies buybacks/treasury stock transactions, whereas this is a new issuance reserved for employees).
2016-06-06 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Remuneration Information Classification · 99% confidence The document is a press release dated June 6, 2016, announcing the launch of an employee share ownership plan ('opération d'actionnariat salarié'). It details the objectives, framework (including authorization from the AGM on May 27, 2015), subscription terms, pricing (€43.15), eligibility, and the indicative calendar for the offering. This type of announcement, which details a specific corporate financing or capital structure event involving employees (share issuance/subscription), aligns best with the 'Capital/Financing Update' category, as it describes the mechanism for issuing new shares to employees, which is a form of capital change/fundraising activity. It is not a general earnings release (ER), a full annual report (10-K), or a simple dividend notice (DIV). It is a specific announcement about capital structure change via employee share offering, fitting the 'CAP' definition.
2016-06-06 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 92% confidence The document is a press release dated June 6, 2016, announcing positive subgroup analysis results from the Phase 3 METEOR trial for CABOMETYX™ (cabozantinib) presented at the 2016 ASCO Annual Meeting. It details clinical efficacy data (Progression-Free Survival (PFS) and Overall Survival (OS)) and includes quotes from management and detailed tables summarizing the results. This content structure—announcing clinical data presentation and summarizing key findings—is characteristic of an Earnings Release (ER) or a general announcement related to clinical progress, but given the focus on presenting specific trial data that is not the full financial report, it aligns best with an Earnings Release (ER) which often includes key operational/clinical highlights, or potentially an Investor Presentation (IP) if it were structured as slides. However, since it is a formal press release detailing results and management commentary, and not a transcript (CT) or a formal regulatory filing like a 10-K, the closest fit among the options for a major announcement of period-specific results (even if clinical rather than quarterly financials) is the Earnings Release (ER), or potentially an Investor Presentation (IP) if it were more graphical. Given the format is a news release detailing trial results presented at a conference, it functions as a major operational/clinical update. Since it is not a formal financial report (10-K, IR) or a presentation deck (IP), and it is announcing significant results, ER is the most appropriate classification for a major corporate announcement of performance/trial outcomes. FY 2016
2016-06-06 French
Communicated under the obligation to provide permanent information / Other communications
Investor Presentation Classification · 95% confidence The document is a press release announcing positive overall survival results from subgroup analyses of a Phase 3 clinical trial (METEOR) for the drug CABOMETYX™, presented at the 2016 ASCO annual meeting. It details efficacy data (PFS and OS) across various patient subgroups and references prior regulatory actions (FDA approval, EMA validation). This content is characteristic of an announcement summarizing clinical trial data and scientific presentations, which falls under the scope of Investor Presentation (IP) or potentially an Earnings Release (ER) if it were tied to a specific reporting period's results. However, since it is a detailed scientific update focused on clinical trial data presentation at a major conference (ASCO), 'Investor Presentation' (IP) is the most fitting category, as these types of data releases are frequently used in investor briefings. It is not a full regulatory report (10-K, IR) nor a general regulatory announcement (RNS).
2016-06-06 English
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 95% confidence The document is a press release dated June 5, 2016, jointly issued by Exelixis and Ipsen, announcing the overall survival (OS) results from the Phase 3 METEOR trial of CABOMETYX™ for advanced renal cell carcinoma. It details clinical data, mentions presentation at the ASCO Annual Meeting, and references publication in *The Lancet Oncology*. This content structure—announcing clinical trial results, providing executive commentary, and detailing trial methodology—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/clinical news. Since the primary focus is the announcement of financial/clinical results (survival data), and it is not a full quarterly report (IR) or a transcript (CT), the most appropriate classification is Earnings Release (ER), as these often include key clinical milestones for biotech/pharma companies alongside financial highlights, or sometimes a general Regulatory Filing (RNS) if it's purely clinical. Given the context of announcing trial results which often accompany or precede earnings announcements, ER is a strong fit, but since it is a specific clinical data release, it could also be considered a general Regulatory Filing (RNS) if it doesn't contain standard quarterly financial tables. However, based on the provided definitions, this is a high-impact announcement of clinical data that drives investor interest, similar to an ER. Since it is a press release announcing key data, and not a formal regulatory filing like a 10-K or IR, and it's not a presentation (IP) or a transcript (CT), ER (Earnings Release - initial announcement of periodical results/key highlights) is the best fit for a major data readout press release. FY 2016
2016-06-05 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.